contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


articles-of-association-for-novo-nordisk-as-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

https://www.bizjournals.com/triangle/news/2026/03/24/novo-nordisk-wegovy-hd-fda-approval.html High-dose Wegovy gets the green light from the FDA.  This was old news anyway, and people are pretty tired of owning this stock  - but I’ll post it regardless.

https://yle.fi/a/74-20216290 Quite a short article, with a few interesting highlights below. A study with nearly 100,000 participants over a 13-year follow-up period.  The use of diabetes and weight loss medications significantly alleviated patients’ mental health problems in a recent international study. The effect was most pronounced in patients who used semaglutide, i.e., the weight loss drugs Ozempic or Rybelsus. The study dispels previous fears that these medications would increase suicidal thoughts. According to the study, the number of sick leaves decreased by 47 percent. More than 800 million people worldwide suffer from type 2 diabetes, and they have twice the risk of depression compared to the general population. … Could diabetes or weight loss medications be beneficial for those who suffer from depression but are not overweight? Research director Markku Lähteenvuo from the University of Eastern Finland considers it possible. … The study involved nearly 100,000 individuals, of whom over 20,000 had used GLP-1 medications. These include diabetes and weight loss drugs. Participants were followed using Swedish national registers between 2009 and 2022.

The article below doesn’t really concern Novo as an investment, but I thought it might still be of interest in this thread.  The article tells how GLP-1 drugs developed by Eli Lilly and Novo Nordisk are changing the food markets so much that food giants have to adapt to people’s new eating habits caused by these drugs. The success of pharmaceutical companies forces businesses to emphasize protein and smaller portion sizes, as consumers’ hunger and snacking decrease. In the future, more pill-form medications could further expand the user base, making pharmaceutical giants indirect trendsetters for the entire global restaurant industry and trade.  Key Points  For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, according to the KFF Health Tracking Poll. About 70% of GLP-1 users who report consuming fewer calories said that they are snacking less, according to a survey conducted by EY-Parthenon last spring.   https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html

Here is an enlightening article about patent expirations in India; those in the know can correct if there are errors in the piece: Lihavuuslääkkeen h-hetki perjantaina – voi puolittaa hinnan - Ilta-Sanomat

Usage growth has been strong in Finland. I’m not surprised, though, as this is the “promised land” of cardiovascular diseases. I suppose this is a general trend at least in developed countries, especially now that Novo offers a pill alternative. For Novo, however, competition is intensifying all the time, even though the market for weight-loss drugs is growing rapidly. People would rather take a pill than exercise more and change their diet to be healthier without medication. In a way, this is a fairly large-scale human experiment, as weight-loss drugs are a new invention and the long-term effects of using the medication are unknown (e.g., 50 years in a row).

IS and IL also have stories today. Lihavuuslääkkeiden käyttö räjähti – näin paljon käyttäjiä oli viime vuonna - Ilta-Sanomat

5 minutes and an Ozempic prescription from a chat doctor, now even in Finland:                   Yle Uutiset – 17 Mar 26              Mika sai Ozempicia laihtumiseen parissa tunnissa – laihdutusprofessori:...    Laihdutuslääkkeitä käytti viime vuonna yli 100 000 suomalaista. MOT:n selvityksen mukaan chattilääkärit kirjoittavat reseptejä jopa näkemättä potilasta.                             Behind the link is a Yle article about how effortless it is to obtain that prescription through these private medical clinics and the risks associated with such practices.

Novo Nordisk

Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026 

Articles of Association for Novo Nordisk A/S 2026 Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/e3b6f836-93fc-48f3-8320-49b7314d89da">AOA260326-NN Articles of Association 2026</a> </li> </ul><img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3MjYzMiM0MDIzNjU1MTMjMjAwMjU2MQ=="> <img alt="" src="https://ml-eu.globenewswire.com/media/Y2RmMTEwN2QtMTE2Ni00OGJjLWEzNmEtYTY3NDE3NDViMzllLTEwMTQxMzQtMjAyNi0wMy0yNy1lbg==/tiny/Novo-Nordisk-A-S.png">